Skip to main content

Table 2 Association between hepatoblastoma risk and NRAS rs2273267 A > T polymorphisms after stratification by age, gender, and clinical stages

From: NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children

Variables

rs2273267 (patients/controls)

Crude OR (95% CI)

P

Adjusted ORa (95% CI)

P a

AA/AT

TT

Age, months

 < 17

102/414

12/40

1.22 (0.62–2.41)

0.571

1.23 (0.62–2.43)

0.556

 ≥ 17

89/467

10/37

1.42 (0.68–2.96)

0.351

1.42 (0.68–2.96)

0.350

Gender

 Female

72/348

12/31

1.87 (0.92–3.82)

0.085

1.84 (0.90–3.77)

0.094

 Male

119/533

10/46

0.97 (0.48–1.99)

0.942

0.97 (0.47–1.97)

0.925

Clinical stages

 I + II

84/881

13/77

1.77 (0.94–3.32)

0.075

1.77 (0.94–3.32)

0.075

 III + IV

48/881

7/77

1.67 (0.73–3.81)

0.225

1.66 (0.73–3.80)

0.229

  1. OR odds ratio, CI confidence interval
  2. aAdjusted for age and gender, with the stratification factor omitted